[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350809-105":59,"doc-detail-350809-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","method-development-for-pancreatic-and-ovarian-cancer-baseline-ctdna-detection-and-measurable-residual-disease-monitoring","Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoring","","Pancreatic and ovarian cancer are difficult to diagnose early, and obtaining endoscopic biopsy tissue can be challenging. Within the Instand-NGS4P framework, measurable residual disease (MRD) blood-based prototypes were developed to support cost-effective differential diagnosis of suspected pancreatic or ovarian neoplasms. The method profiles blood plasma for cell-free DNA mutations in cancer-relevant genes, applying unique molecular identifiers for bioinformatic error correction. Using reference standards, stable detection was demonstrated down to 0.1% variant allele frequency with limited false positives, mitigating them via filtering.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/method-development-for-pancreatic-and-ovarian-cancer-baseline-ctdna-detection-and-measurable-residual-disease-monitoring/350809/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/method-development-for-pancreatic-and-ovarian-cancer-baseline-ctdna-detection-and-measurable-residual-disease-monitoring/350809.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this MRD prototype address for pancreatic and ovarian cancer?","Question",{"text":112,"@type":113},"Early diagnosis is challenging and tissue biopsy retrieval can be difficult. The prototype uses blood plasma to support differential diagnosis of suspected pancreatic or ovarian neoplasms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the method detect mutations in circulating tumor DNA?",{"text":117,"@type":113},"It examines blood plasma for cell-free DNA mutations in specific genes linked to pancreatic or ovarian neoplasms. Unique molecular identifiers (UMIs) are used to enable bioinformatic error correction.",{"name":119,"@type":110,"acceptedAnswer":120},"What sensitivity and accuracy results are reported?",{"text":121,"@type":113},"Stable mutation detection is demonstrated down to a variant allele frequency (VAF) of 0.1%. At 4,000x duplex consensus reads, only two false positives were observed and can be mitigated using an appropriate filtering strategy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350809,1790882951,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Open Research Europe Open Research Europe 2026, 6:87 Last updated: 13 JUL 2026  \nMETHOD ARTICLE  \nMethod development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease  \nmonitoring  \n[version 1; peer review: 2 approved with reservations]  \nTim Alexander Steiert 1, Philipp M. Altrock2, Axel Künstner3, Vishal Dixit4, Burkhard Brandt5, Pamela Pinzani 6, Hauke Busch3, Andre Franke 1, Michael Forster 1  \n1Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, 24118, Germany  \n2 Department of Hematology and Oncology, Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, 24105, Germany  \n3 Medical Systems Biology Group, Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Schleswig-Holstein, 23538, Germany  \n4Twist Bioscience, Inc., South San Francisco, California, 94080, USA  \n5Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Schleswig-Holstein, 24105, Germany  \n6 Department of Experimental and Clinical Biomedical Sciences, University of Florence and Molecular and Clinical Biochemistry Unit, Careggi University Hospital, Florence, Tuscany, 50139, Italy  \nv1  \nFirst published: 03 Apr 2026, 6:87  \n[https://doi.org/10.12688/openreseurope.23403.1](https://doi.org/10.12688/openreseurope.23403.1)  \n[Latest published:](Latest published: 13 Jul 2026)[ 13 Jul 2026](Latest published: 13 Jul 2026), 6:87  \n[https://doi.org/10.12688/openreseurope.23403.2](https://doi.org/10.12688/openreseurope.23403.2)  \nAbstract  \nBackground  \nPancreatic cancer and ovarian cancer are very challenging to diagnose at early stages. The endoscopic retrieval of biopsy tissue from a suspected benign or malignant lesion is challenging due to the tissue’s nature. Therefore, within the Instand-NGS4P framework, we developed Measurable Residual Disease (MRD) prototypes to analyze blood plasma samples, with the aim of cost-effectively supporting the differential diagnosis of suspected pancreatic or ovarian neoplasms.  \nMethods  \nOur MRD prototypes examine blood plasma for mutations in cell-free DNA in specific genes associated with pancreatic neoplasms or ovarian neoplasms, respectively. Unique molecular identifiers (UMIs) are used to enable bioinformatic error correction. Ultra-deep  \nOpen Peer Review  \n\n| Approval Status  |  |\n| --- | --- |\n| 1 | 2 |\n| version 2\u003Cbr>(revision)\u003Cbr>13 Jul 2026\u003Cbr>version 1  \u003Cbr>view view\u003Cbr>03 Apr 2026 |  |\n\n1. Myron G. Best , Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands  \n2. Yibo Dai, The University of Texas MD Anderson Cancer Center, Houston, USA  \nAny reports and responses or comments on the  \narticle can be found at the end of the article.  \nsequencing is demonstrated on sequencing platforms from two different vendors (Illumina and MGI) . We provide detailed information on bioinformatic processing of sequencing data to perform errorcorrection.  \nResults  \nUsing commercially available reference standards, we demonstrate stable mutation detection down to a variant allele frequency (VAF) of 0.1% . At a coverage of 4,000x duplex consensus reads, only two false positives were observed, which can be efficiently mitigated using an appropriate filtering strategy.  \nConclusions  \nThe technical usability of our MRD prototype has been clearly demonstrated for stable low-level VAF detection in commercial reference samples.  \nPlain language summary  \nEarly detection of pancreatic and ovarian cancer is difficult, and tissue biopsies are often hard to obtain. We developed blood-based test prototypes that detect tiny amounts of cancer DNA using highly sensitive sequencing. Using reference samples, we reliably detected mutations at very low levels (0.1%) with few false signals. These results show that the approach is technically robust and suitable for low-level blood-based cance","cbCaiiiPPoMiWduE","https://ap.wps.com/l/cbCaiiiPPoMiWduE","pdf",1696468,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Plain language summary\n## Keywords","[{\"question\":\"What problem does this MRD prototype address for pancreatic and ovarian cancer?\",\"answer\":\"Early diagnosis is challenging and tissue biopsy retrieval can be difficult. The prototype uses blood plasma to support differential diagnosis of suspected pancreatic or ovarian neoplasms.\"},{\"question\":\"How does the method detect mutations in circulating tumor DNA?\",\"answer\":\"It examines blood plasma for cell-free DNA mutations in specific genes linked to pancreatic or ovarian neoplasms. Unique molecular identifiers (UMIs) are used to enable bioinformatic error correction.\"},{\"question\":\"What sensitivity and accuracy results are reported?\",\"answer\":\"Stable mutation detection is demonstrated down to a variant allele frequency (VAF) of 0.1%. At 4,000x duplex consensus reads, only two false positives were observed and can be mitigated using an appropriate filtering strategy.\"}]","Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoring | PDF",1790091234,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7145792017fbd4563e9c37d2d55244f7.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/debb2cf4fb9d7ea8d14679fbf42160cd.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28c0ddcd346eacd7e15719bb71cdb3b2.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21abceaf72d97c8c49c12ebe1f499aa5.webp",980,1268]